Trial Profile
Assessment of Electrophysiological Effects of Tipranavir Co-administered With Ritonavir Given b.i.d. for 2.5 Days on the QT Interval in Healthy Female and Male Subjects. A Double-blind, Randomised, Placebo Controlled, Two-way Crossover Study With a Positive Control (Moxifloxacin) and Parallel Dose Groups
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Tipranavir (Primary) ; Ritonavir
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 05 Nov 2010 New trial record.